anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Defined as CLL/SLL or NHL not otherwise specified in Cohorts 1 through 6, inclusive of CLL/SLL, Richter's transformation, or low grade NHL with transformation, blastoid MCL, and patients with history of CNS involvement or primary CNS lymphoma. In the event the Sponsor electively closes Cohorts 2-4 prior to completion, patients with CLL/SLL who are ineligible to participate in or unable to access late phase studies of pirtobrutinib may be eligible to enroll in this cohort Diffuse large B-cell lymphoma (DLBCL) is excluded. MCL without prior BTK inhibitor treatment is excluded. Patients enrolling to Cohort 7 must have received one or more prior therapies or have no available approved therapy with demonstrated clinical benefit with the exception of untreated Richter's transformation, which is allowed.
In this prospective observational cohort study of pediatric patients requiring home parenteral nutrition for intestinal failure, participants will be enrolled from the pediatric intestinal rehabilitation clinic, and data collection will be obtained from the electronic medical record. Participant will receive daily sodium citrate 4% catheter locking solution for CLABSI prophylaxis, instead of heparin locks. Participants will be monitored for 12 months for adverse events, including CLABSI. Participants will have the same routine laboratory schedule and monthly outpatient follow up. After 12 months, participants will be given the option to continue to use sodium citrate 4% locks after the initial study period if no serious adverse events have occurred. The investigators anticipate enrolling 10-15 participants per year and anticipate enrollment to continue for 3-5 years.

Sodium citrate locks: 3 ml vials of locking solution will be prepared by the infusion pharmacy using commercially available 4% sodium citrate IV fluid (available in 500 ml bags). The sodium citrate locks will be instilled into the central catheter daily during the period that parenteral nutrition is not infusing, and will be withdrawn and disposed of prior to resuming infusion of parenteral nutrition. If subjects are hospitalized, sodium citrate locks will be temporarily held during the duration of the inpatient stay, and will be resumed once the participant is discharged home.
This is a two-year randomized placebo-controlled double-blind investigation of the augmentation of PREG with L-theanine in the management of patients with SZ/SA. The study will consist of two phases: a 2-week continued stability (lead in) phase and an 8-week double-blind treatment phase. In the lead-in phase, patients receiving antipsychotic medication will remain on their maintenance regimen for at least two weeks. Clinical stability is defined as two consecutive weekly CGI ratings with no change in score, and with no more than a 20% change in PANSS total score. The treatment phase will be 8-week parallel groups, placebo-controlled, double-blind trial of adjunctively administered PREG with L-theanine or placebo. Assignment to PREG with L-theanine or placebo will be on a random, stratified (i.e., FGAs/SGAs, inpatient/outpatient) basis. PREG (50 mg/day) with L-theanine (400 mg/day) and placebo will be administered in divided doses in the form of capsules. If a patient relapses during the treatment phase of the study, the patient will be removed from the study. All attempts will be made to obtain end-of-study ratings. If such measures cannot be obtained, four- and six-week data, if collected prior to relapse, will be informative. Patients who fulfill the entry criteria will enter the 8-week double-blind treatment phase of the study. Assignment to PREG with L-theanine or placebo will be on a random, stratified (i.e., conventional/new generation antipsychotic treatment, inpatient/outpatient) basis. PREG (50 mg/day) with L-theanine (400 mg/day)/placebo will be administered in divided doses in the form of white capsules. If a patient relapses during the treatment phase of the study, the patient will be removed from the study. All attempts will be made to obtain end-of-study ratings. If such measures cannot be obtained, four- and eight-week data, if collected prior to relapse, will be informative.

Subjects will be assessed at baseline and after 2, 4, 6, and 8 weeks of treatment using psychiatric rating scales, and self-report questionnaires. Neurobiological (plasma cortisol, PREG, dehydroepiandrosterone, BDNF and other biologically active molecules) and immunological (the pro-inflammatory cytokines and others) testing will be conducted at baseline, and after treatment. The efficacy and safety of augmenting antipsychotic treatment of PREG with L-theanine will be analyzed.
Eligible subjects will receive single dose of paroxetine 25 milligrams controlled release formulation followed by wash-out period of 5 days. Subjects will receive multiple doses of paroxetine 25 milligrams for further 14 days.
The present invention relates to methods of dispensing generic pharmaceutical products to qualified patients, physicians and/or pharmacies. In one embodiment, the methods generally involve a plurality of sources of generic pharmaceutical products transferring generic pharmaceutical products to one or more charitable foundations. The one or more charitable foundations further transfer the generic pharmaceutical products to a centralized sourcing agent and distributor. Alternatively, the sources of generic pharmaceutical products may transfer the same directly to the centralized sourcing agent and distributor. The centralized sourcing agent and distributor compiles information provided by a plurality of patients; using this information and substantially universal criteria, the centralized sourcing agent and distributor identifies patients that are qualified to purchase the received generic pharmaceutical products at reduced prices; and dispenses the received generic pharmaceutical products to qualified patients at their request and in accordance with their prescription. Alternatively, the centralized sourcing agent and distributor may dispense the received generic pharmaceutical products directly to physicians or to pharmacies for future distribution to appropriate patients. Still further, the centralized sourcing agent and distributor may dispense generic pharmaceutical products, which it receives directly from pharmaceutical manufacturers, wholesalers or other sources, to one or more charitable foundations. The one or more charitable foundations may then dispense the appropriate generic pharmaceutical products to qualifying patients, physicians and/or pharmacies.
The present invention discloses the evaluation of the virucidal activity of Fucoidano, Spirulina, and Chlorella, consisting of the cultivation and harvesting of the two microalgae to generate formulations that included their mixtures with Fucoidan, the phenol content, and quantifying the antioxidant potential thereof. Herein, Fucoidan is almost 200% higher in the three measured parameters, observing a predominantly additive synergistic effect with the microalgae in the three parameters (total phenols, DPPH, ABTS). In particular, three mixtures stood out from the rest: Fucoidan with Chlorella (5050), Fucoidan with Spirulina and Chlorella (502525), and Fucoidan with Spirulina and Chlorella (333333) (figure 2). Subsequently, it tests the potential virucidal effects of four mixtures, Fucoidan. The total extracts of Spirulina and Chlorella under two schemes: prophylactic (pretreatment) and simultaneous to SARS-CoV-2 infection, observing that four of the ten formulations developed present p rotection of up to 75% survival in cells exposed to SARS-CoV-2, drastically reducing the cytopathic effect and preserving viability in VERO cells (Figure 3), even in the cells that presented the phenotype of cytopathic when determining their mitochondrial respiration, maintaining said function. Also, it pre-treats the cultures with the mixtures (formulations) for 48 hours, inoculating them with SARS-CoV-2 virus at 24-, 48-, 72-, and 96-hours post-virus inoculation, extracting the nucleic acids to determine any difference between treatments and controls, performing an RT-PGR subsequently by the protocols and materials specified by InDRE. As a result, it founds a distinction between treatments and controls (a lower Ct represents a higher viral load) that the cycle (Ct) of appearance of the positive control for each repetition as an average of 28.91 at 24 hours and the Ct (increased load), decreasing viral as time passed until reaching 17.82 (average) at 96 hours, while in the pretreatme nts with the mixtures of Fucoidan, Spirulina, and Chlorella (33 33 33) they presented an average 26.42 Ct, and for Fucoidan, Spirulina and Chlorella ( 50 25 25) is 26.73 Ct on average at 24 hours, which with the time this amount of Ct preserved in both mixtures and at 96 hours 28.03 and 27.81, recorded respectively. Said results show differences of approximately ten cycles compared to the control, meaning there is no viral replication, observing a virucidal effect against SARS-CoV-2. Additionally, said differences conclude that the mixtures presented unprecedented protection in the cells, demonstrating a positive drug interaction enhancing the effects observed against SARS CoV-2 in vitro VERO cell models and verifying the ability of the Alquimar Fucoidan compound combined with spirulina microalgae to function with antiviral and anti-COVID-19 activity.
PURPOSE:To obtain the titled composition effective to control the releasability in the body to enable the reduction of the administration frequency, by compounding a cellulose derivative and a hydrolyzed methoxyethylene maleic anhydride copolymer to a drug. CONSTITUTION:A drug which is necessarily administered frequently to keep the effective blood concentration or topical concentration (e.g. mefenamic acid, indomethacin, etc.) is compounded with hydrolyzed methoxyethylene maleic anhydride copolymer of formula and a cellulose derivative (e.g. cellulose ether) to obtain the objective slow-releasing pharmaceutical composition. The slow- releasing pharmaceutical preparation obtained by adding the drug to the mixture has the bio-adhesivity and biocompatibility of hydrolyzed methoxymethylene maleic anhydride copolymer as well as the shape-retainability of a certain kind of cellulose derivative and the frequency of administration can be decreased. It is preferable that at least 50% of the maleic anhydride group is converted to carboxylic acid group by hydrolysis.
Carcinoma of the gallbladder is the commonest malignancy of the biliary tract. United states has an incidence of 1/100000.Higher incidence has been noted in Chile, Mexico and Southwest American Indians. It is the third most common malignancy in India. The disease may mimic benign disease in presentation. Now 78-85% of the cases may be detected preoperatively with radiological imaging. 1-3% of the carcinoma of the gall bladder may be detected incidentally. Up to 1/3rd of patients may present with jaundice but of these only 7% will be resectable. With aggressive surgical resection, actuarial 5 year survival of 83% for stage II disease and 63% for stage III have been reported. Treatment of choice is complete surgical resection.

The role of chemotherapy and radiotherapy is not very well documented in treatment of gallbladder cancer. Because of the propensity of gallbladder carcinoma to spread to regional lymph nodes at an early stage and the high rate of loco regional recurrence, adjuvant chemotherapy or chemo-radiotherapy seems a rational therapeutic option. The chemotherapies are based on 5 Fluorouracil with or without radiotherapy. Gemcitabine with or without Cisplatin has been increasingly used. In a recent paper Gemcitabine with Cisplatin was found to be more effective than gemcitabine alone and provides definite survival advantage and progression free survival. An earlier randomized trial done to assess the efficacy of the adjuvant chemotherapy for the pancreato-biliary cancer reported improvement in disease free and overall 5 year survival. But this study has included patients with suboptimal resection and all pancreato-biliary malignancy.

In view of these observations this study is being designed to assess the efficacy of the chemotherapy in the adjuvant setting in gallbladder cancer patients who have undergone curative resections.
Solutions should be stored at 20° to 25°C (68° to 77°F); excursion permitted between 15 ⁰ C to 30 ⁰C (59 ⁰ F to 86 ⁰ F) [see USP Controlled Room Temperature]. 

These solutions are not for spinal anesthesia.

SENSORCAINE®-MPF (methylparaben free) does not contain epinephrine and is clear and colorless. Do not use the solution if it is discolored or if it contains a precipitate. SENSORCAINE®-MPF is available in the following forms: 

SENSORCAINE®\- MPF WITH EPINEPHRINE (1:200,000) should be protected from light. This product is clear, colorless to slightly yellow. Do not use the solution if it is pinkish or darker than slightly yellow or if it contains a precipitate. SENSORCAINE®-MPF WITH EPINEPHRINE is available in the following forms: 

For Single Dose Vials: Discard unused portion. 

SENSORCAINE® (preserved with methylparaben) does not contain epinephrine and is clear and colorless. Do not use the solution if it is discolored or if it contains a precipitate. SENSORCAINE® is available in the following forms: 

SENSORCAINE® WITH EPINEPHRINE (1:200,000) should be protected from light. This product is clear, colorless to slightly yellow. Do not use the solution if it is pinkish or darker than slightly yellow or if it contains a precipitate. SENSORCAINE® WITH EPINEPHRINE is available in the following forms:
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs such as ASCOMP with Codeine. Some of these events have been fatal or life threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue ASCOMP with Codeine and evaluate the patient immediately.
Recent studies suggesting an effect of cardiovascular therapies to prevent diabetes remain unexplained. We hypothesize that these therapies improve vascular endothelial function allowing improved actions of insulin in the vasculature, which comprise a significant portion of insulin's metabolic action. We therefore propose to measure insulin-mediated glucose disposal and insulin-mediated vasodilation before and after 12 weeks' therapy with Losartan (an angiotensin receptor blocker) or placebo, in a randomized design. Subjects will include 28 subjects with impaired glucose tolerance, which is generally accompanied by both insulin resistance and impaired vascular function. With this number of participants we have a 90% chance of showing a statistically significant and clinically meaningful effect of insulin on leg vascular resistance, and an even higher chance of showing a difference in insulin's metabolic effects. Exclusion criteria will include frank hypertension, diabetes, or hypercholesterolemia, and biochemical or other contraindications to losartan therapy. The primary endpoint for statistical analysis will be the invasive measure of insulin-stimulated endothelial function. We anticipate an improvement in both vascular and metabolic measures of insulin action following Losartan therapy but no change from untreated baseline following placebo.
BACKGROUND: High-potassium intake is associated with a lower risk of cardiovascular disease. However, the association between potassium intake and the development of chronic kidney disease (CKD) remains unclear.
OBJECTIVE: The objective of this study was to investigate whether potassium intake is associated with outcomes of incident CKD.
METHODS: This is a population-based prospective observational cohort study from the UK Biobank cohort between 2006 and 2010. We included 317,162 participants without CKD from the UK Biobank cohort. The main predictor was spot urine potassium-to-creatinine ratio (KCR). The primary outcome was incident CKD, which was defined by the International Classification of Disease 10 codes or Operating Procedure Codes Supplement 4 codes.
RESULTS: At baseline, individuals with higher KCR had lower blood pressure, body mass index, and inflammation, and were less likely to have diabetes and hypertension. During a median follow-up of 11.9 y, primary outcome events occurred in 15,246 (4.8%) participants. In the cause-specific model, the adjusted hazard ratio (aHR) per 1-standard deviation increase in KCR for incident CKD was 0.90 [95% confidence interval (CI): 0.89, 0.92]. Compared with quartile 1 of KCR, the aHRs (95% CIs) for quartiles 2-4 were 0.98 (0.94, 1.02), 0.90 (0.86, 0.95), and 0.80 (0.76, 0.84), respectively. In sensitivity analysis with different definitions of CKD, the results were similar. In addition, further analysis with dietary potassium intake also showed a negatively graded association with the primary outcome.
CONCLUSIONS: Higher urinary potassium excretion and intake were associated with a lower risk of incident CKD.
Chronic constipation is one of the most common gastrointestinal disorders worldwide. Due to changes in diet, lifestyle, and the aging population, the incidence of chronic constipation has increased year by year. It has had an impact on daily life and poses a considerable economic burden. Nowadays, many patients with chronic constipation try to seek help from complementary and alternative therapies, and traditional Chinese medicine (TCM) is often their choice. The intestinal flora play an important role in the pathogenesis of constipation by affecting the body's metabolism, secretion, and immunity. Regulating the intestinal flora and optimizing its composition might become an important prevention and treatment for chronic constipation. TCM has unique advantages in regulating the imbalance of intestinal flora, and its curative effect is precise. Therefore, we reviewed the relationship between intestinal flora and chronic constipation as well as advances in research on TCM as adjunct therapy in the management of chronic constipation by regulating intestinal flora. Some single Chinese herbs and their active ingredients (e.g., Rheum palmatum, Radix Astragalus, and Cistanche deserticola), some traditional herbal formulations (e.g., Jichuan decoction, Zengye decoction, and Zhizhu decoction) and some Chinese patent medicines (e.g., Maren pills and Shouhui Tongbian capsules) that are commonly used to treat chronic constipation by regulating intestinal flora are highlighted and summarized. Moreover, some external forms of TCM, and especially acupuncture, have also been found to improve intestinal movement and alleviate constipation symptoms by regulating intestinal flora. We hope this review can contribute to an understanding of TCM as an adjunct therapy for chronic constipation and that it can provide useful information for the development of more effective constipation therapies.
The HIV genome contains a number of genes that regulate viral replication. Control of the activity of these genes and their encoded proteins represents a potential target for development of new antiretroviral drugs. The tat (transactivator of transcription of HIV) antagonist Ro 24-7429 is the first compound for clinical testing that utilizes this approach for therapy of HIV infection.

Ninety-six patients (four treatment arms of 24 patients each) are randomized to receive oral Ro 24-7429 at 1 of 3 doses or nucleoside control (either zidovudine or didanosine). The study will be blinded only for the arms receiving Ro 24-7429. Treatment continues for 12 weeks. After 12 weeks, patients on the nucleoside control arm receive the highest tolerated dose of Ro 24-7429 in addition to their nucleoside.
Acute otitis media (AOM) is a common diagnosis in children who present with symptoms of otalgia, fever, or irritability and is confirmed by a bulging tympanic membrane or otorrhea on physical examination. It often is preceded by a viral infection, but the bacterial pathogens isolated most commonly are Streptococcus pneumonia, Haemophilus influenzae, and Moraxella catarrhalis. Watchful waiting may be appropriate in children 6 months or older with uncomplicated unilateral AOM. When antibiotics are indicated, amoxicillin is the first-line treatment in those without recent treatment with or allergy to this drug. Otitis media with effusion (OME) is fluid in the middle ear without symptoms of AOM and typically resolves within 3 months. Tympanostomy tube placement is the most common ambulatory surgery for children in the United States. It is used to ventilate the middle ear space and may be performed to treat recurrent AOM, persistent AOM, or chronic OME. Acute otitis externa is inflammation of the external ear canal, often due to infection. On examination, the ear canal is red and inflamed, with patients typically experiencing discomfort with manipulation of the affected ear. It is treated with a topical antibiotic with or without topical corticosteroid.
LncRNAs play an important role in autoimmune diseases. The purpose of this study was to explore the role of lncRNA SNHG1 in systemic lupus erythematosus (SLE), and laid a theoretical foundation for the study of SLE. The basic clinical information of all subjects was first collected for statistical analysis, and SNHG1 expression in the serum of all subjects was detected by RT-qPCR. The value of SNHG1 in the diagnosis of SLE was assessed by ROC. The correlation between SNHG1 and each blood sample index was analyzed by Pearson correlation analysis. The role of SNHG1 in primary peripheral blood mononuclear cells (PBMCs) apoptosis was explored. SNHG1 expression is relatively upregulated in patients with SLE compared to healthy people. SNHG1 expression was positively correlated with SLEDAI score, IgG, CRP, and ESR, and negatively correlated with C3 and C4. ROC indicated that SNHG1 has the potential to assist in the diagnosis of SLE. PBMCs apoptosis in SLE was higher than that in control group, the knockdown and overexpression of SNHG1 could correspondingly inhibit and promote PBMCs apoptosis. SNHG1 has the potential to be a diagnosis marker for SLE and may be involved in regulating PBMCs apoptosis.